US SB2004 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on June 27 2019 - 25% progression, died in committee
Action: 2019-06-27 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 27 2019 - 25% progression, died in committee
Action: 2019-06-27 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin. Specifically, the bill requires the Centers for Disease Control and Prevention to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual’s health plan deductible. Further, the Department of Health and Human Services (HHS) must collect annual fees from insulin manufacturers, based on each manufacturer’s market share, equal to the total estimated expenditures under the insulin grants program. Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.
Title
Emergency Access to Insulin Act of 2019
Sponsors
Sen. Tina Smith [D-MN] | Sen. Kevin Cramer [R-ND] |
History
Date | Chamber | Action |
---|---|---|
2019-06-27 | Senate | Read twice and referred to the Committee on Finance. |
Same As/Similar To
HB4010 (Same As) 2019-07-26 - Referred to the Subcommittee on Health.
Subjects
Accounting and auditing
Business ethics
Business records
Competition and antitrust
Congressional oversight
Digestive and metabolic diseases
Government information and archives
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Health programs administration and funding
Health technology, devices, supplies
Indian social and development programs
Inflation and prices
Intergovernmental relations
Licensing and registrations
Manufacturing
Minority health
Performance measurement
Prescription drugs
Public contracts and procurement
Public-private cooperation
Retail and wholesale trades
Sales and excise taxes
State and local finance
State and local government operations
Business ethics
Business records
Competition and antitrust
Congressional oversight
Digestive and metabolic diseases
Government information and archives
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Health programs administration and funding
Health technology, devices, supplies
Indian social and development programs
Inflation and prices
Intergovernmental relations
Licensing and registrations
Manufacturing
Minority health
Performance measurement
Prescription drugs
Public contracts and procurement
Public-private cooperation
Retail and wholesale trades
Sales and excise taxes
State and local finance
State and local government operations
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/2004/all-info |
Text | https://www.congress.gov/116/bills/s2004/BILLS-116s2004is.pdf |